Navigation Links
EpiCept Corporation Announces Pricing of Public Offering
Date:12/4/2007

opment of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 or EPC 2407 will not be successful, that NP-1 or EPC 2407 will not receive regulatory approval or achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings which are available at http://www.sec.gov or at http://www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

EPCT-GEN

* Azixa is a registered trademark of Myriad Genetics, Inc.


'/>"/>
SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
9. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
10. Brooke Franchise Corporation Announces Selected July Results
11. MedThink Communications Retained by NanoBio Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 05, 2015 Understanding China’s New ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/UnderstandingChinaMDRegs ... revamped regulations for medical devices in China. , ... devices — research and development, approval, manufacturing, distribution, and ... those currently in development as well as those that ...
(Date:3/4/2015)... NV (PRWEB) March 04, 2015 In the ... the fight that is the main event. For UFC ... that fight will be for the UFC Featherweight Championship. Brazilian ... brash, often out-spoken native of Ireland, Conor “Notorious” McGregor. UFC ... Grand Garden Arena in Las Vegas, NV. , When it ...
(Date:3/4/2015)... 2015 When people talk about venues being ... spread across numerous genres, the Houston Rodeo will ... night during the annual livestock show and rodeo, one popular ... other activities being held at the event. The 2015 show ... that will try and get the festival its largest attendance ...
(Date:3/4/2015)... TROY Healthcare Solutions will be introducing TROY ... level of security for prescriptions, in Houston, Texas on ... Center located at 6633 Travis Street from 7 AM ... TROY Healthcare Solutions will host a continental breakfast. Starting ... presentations each hour to introduce attendees to TROY Secure ...
(Date:3/4/2015)... March 04, 2015 The ability ... in density assessment and help improve breast cancer ... abstracts accepted for presentation at the European Congress ... Ten abstracts - eight posters and 2 session ... automated breast density and quantitative breast imaging software ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 2Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 3Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 2Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 3Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 2Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 3Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5
... completion may boost patient compliance, outcomes, researchers say , , ... antibiotic called moxifloxacin in combination with other drugs could ... takes to cure patients with drug-treatable tuberculosis, according to ... result in patients failing to complete their drug therapy, ...
... highly recruited adapted sports athletesGOLDEN VALLEY, Minn., April 2 ... Center has had a history of developing talented, nationally ... wheelchair basketball and rugby. On Thursday, April 9, at ... college letters of intent in the Gym at Courage ...
... announced the release of the first long-range plan for ... million Americans each year. , Opportunities and Challenges in ... Digestive Diseases describes the impact of diseases ranging from ... out priorities for research over the next 10 years. ...
... Holdings, Inc. announced today that it has agreed to ... Physicians Investment Network, LLC, which is owned primarily by ... and certain related parties of OC-PIN. The litigation ... May, 2007 against two of its former directors and ...
... Streamline Health Solutions, Inc. (Nasdaq: STRM ) ... year 2008 financial results for the period ended January 31, ... The Company will conduct a conference call and web ... 4:30 p.m. ET.Interested parties can access the call by dialing ...
... 2 In a press conference today, Colgate and,the ... la Salud,Bucal: Un Mundo de Sonrisas Saludables (Oral Health ... ongoing commitment to quality oral care among the,Hispanic community. ... and lack of familiarity accessing oral,healthcare services, among other ...
Cached Medicine News:Health News:New Antibiotic Could Shorten TB Treatment 2Health News:Courage Center Hosts College Scholarship Signing Ceremony Thursday, April 9, 2009 2Health News:NIH releases the first research plan to reduce the burden of digestive diseases 2Health News:NIH releases the first research plan to reduce the burden of digestive diseases 3Health News:IHHI Settles Litigation With OC-PIN 2Health News:Streamline Health to Announce Q4 and Fiscal Year 2008 Financial Results on Thursday, April 9, 2009 2Health News:Streamline Health to Announce Q4 and Fiscal Year 2008 Financial Results on Thursday, April 9, 2009 3Health News:Colgate and the Hispanic Dental Association Proclaim April El Mes de la Salud Bucal to Promote Oral Health Fundamentals Among Hispanics 2Health News:Colgate and the Hispanic Dental Association Proclaim April El Mes de la Salud Bucal to Promote Oral Health Fundamentals Among Hispanics 3
(Date:3/4/2015)... March 4, 2015 The March 3, 2015, order from ... must change their products, labels to clarify the drugs, intended ... and stroke is necessary to protect the public from injury ... partner at Simmons Hanly Conroy . The ... that the products – currently taken by millions of U.S. ...
(Date:3/4/2015)... CITY, Kan. , March 4, 2015   ... a pet therapeutics company focused on the licensing, development ... today announced that it will present at the ... 10-12, 2015, at the Loews Miami Beach Hotel in ... Steven St. Peter , M.D., President and Chief ...
(Date:3/4/2015)... N.J. , March 4, 2015  Bayer ... Drug Administration (FDA) has accepted the company,s Biologics ... Factor VIII compound.  Bayer is seeking FDA approval ... for the treatment of hemophilia A in children ... to continually bringing new therapies to hemophilia A ...
Breaking Medicine Technology:Simmons Hanly Conroy, LLC: FDA Orders Label Warnings on Testosterone Drugs Concerning Normal Aging Use and Heart Attack-Stroke Risks 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3
... , May 10 /PRNewswire-Asia/ -- On April ... cases with Beijing Un-Assegai Technical &,Trade Co. Ltd. (hereinafter referred ... China , as claimant and U.S. Abbott,Laboratories (Abbott U.S.; ... by the,China International Economic and Trade Arbitration Commission (CIETAC), which,has ...
... , Fla., May 10 Dr. Richard ... with newly diagnosed type 1 diabetes for Protege Encore, a ... of two Phase III studies testing the safety and efficacy ... as Protege, has completed enrollment of more than 530 subjects ...
Cached Medicine Technology:Assegai Wins Big Settlement Against ABBOTT's Subsidiary 2Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes 2
... enables highly sensitive time-resolved fluorescence detection ... fluorophores. These compounds are excited with ... fluorescence lifetimes (several hundred microseconds), large ... profiles at 620 nm. Therefore with ...
... most advanced multi-functional microplate detection system, ... performance without compromising flexibility. ,The ... on the Ultra instrument platform. New ... adds to the flexibility of the ...
... OPTIMA is a fully automated microplate ... different measurement principles:, , Fluorescence Polarization ... Fluorescence , High-Performance Luminescence (flash ... ,It is designed for the ...
... FLUOstar is a flexible multifunction plate reader ... one instrument: fluorescence intensity, time-resolved fluorescence, high-perfomance ... be equipped with injectors that deliver reagent ... fast kinetic cell assays can be performed ...
Medicine Products: